David Ridley
@davidridley.bsky.social
📤 53
📥 41
📝 7
Health economist, priority review voucher co-author, and basketball fan working at Duke University.
In 2003, Médecins Sans Frontières (Doctors Without Borders) launched the Drugs for Neglected Diseases initiative (
@dndi.org
) to create affordable treatments for neglected illnesses. It's a remarkable story of do-gooders becoming drug makers.
about 2 months ago
1
3
0
If you're in the Triangle area and curious about the human microbiome, the science behind taste, or how benign parasites might impact medicine, join us at
@fuqua.duke.edu
on March 20 at 12:45 in the Kirby Reading Room for a talk by Rob Dunn, biologist and author of "Delicious" and other books.
10 months ago
1
4
1
If a drugmaker increases its commercial price over time, it must pay a rebate to the US government. This somewhat dampens price increases and lowers the net price paid by the government. But what if the drugmaker resets its price by launching a new version?
@warren.senate.gov
wants an investigation.
loading . . .
https://www.warren.senate.gov/imo/media/doc/2024.03.01_Letter_to_GSK_on_Flovent_HFA.pdf
10 months ago
0
1
0
Less is often more, according to Shelley Hwang, MD, MBA, of @DukeU. In @JAMA_current, she and coauthors demonstrated that monitoring is a safe, less invasive approach for low-risk ductal carcinoma in situ (DCIS). Video:
youtu.be/_fuC8cFlsXU
Article:
jamanetwork.com/journals/jam...
loading . . .
Dr. Shelley Hwang - Surgical Oncologist, Mountain Climber
YouTube video by Duke University School of Medicine
https://youtu.be/_fuC8cFlsXU
about 1 year ago
0
3
0
In 2024, @US_FDA approved 50 novel drugs, including: • 34 first approved in the US • 26 orphan drugs (<200K Americans affected) • 7 accelerated approvals (conditional approval on surrogate endpoints) • 28 priority reviews (6-month FDA review) Cancer drug Bizengri was all 4.
about 1 year ago
1
0
0
you reached the end!!
feeds!
log in